Hosted on MSN
REPL stock lost 19% of its value today – why did the FDA refuse approval for its experimental melanoma drug?
・The FDA previously rejected approval for RP1 in July. ・The agency noted that the members of the team who reviewed the resubmission were different from those who reviewed the initial application to ...
Hosted on MSN
Replit edges ahead in AI coding tool showdown
A head-to-head test of four AI coding tools—Claude Code, Codex, Lovable, and Replit—found Replit delivering the most polished, fully deployable app. While Claude Code and Codex produced functional ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results